Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER Insights and Implications

被引：23

作者：

Ridker, Paul M. ^{[1
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA USA

来源：

CIRCULATION | 2018年 / 137卷 / 17期

关键词：

atherosclerosis; canakinumab; evolocumab; mortality; prevention and control; randomized controlled trials as topic; C-REACTIVE PROTEIN; SECONDARY ANALYSIS; TRIAL;

D O I：

10.1161/CIRCULATIONAHA.117.033254

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1763 / 1766

页数：4

共 5 条

[1] Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial [J].

Giugliano, Robert P. ;

Pedersen, Terje R. ;

Park, Jeong-Gun ;

De Ferrari, Gaetano M. ;

Gaciong, Zbigniew A. ;

Ceska, Richard ;

Toth, Kalman ;

Gouni-Berthold, Ioanna ;

Lopez-Miranda, Jose ;

Schiele, Francois ;

Mach, Francois ;

Ott, Brian R. ;

Kanevsky, Estelle ;

Pineda, Armando Lira ;

Somaratne, Ransi ;

Wasserman, Scott M. ;

Keech, Anthony C. ;

Sever, Peter S. ;

Sabatine, Marc S. .

LANCET, 2017, 390 (10106) :1962-1971

[2] Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease [J].

Ridker, P. M. ;

Everett, B. M. ;

Thuren, T. ;

MacFadyen, J. G. ;

Chang, W. H. ;

Ballantyne, C. ;

Fonseca, F. ;

Nicolau, J. ;

Koenig, W. ;

Anker, S. D. ;

Kastelein, J. J. P. ;

Cornel, J. H. ;

Pais, P. ;

Pella, D. ;

Genest, J. ;

Cifkova, R. ;

Lorenzatti, A. ;

Forster, T. ;

Kobalava, Z. ;

Vida-Simiti, L. ;

Flather, M. ;

Shimokawa, H. ;

Ogawa, H. ;

Dellborg, M. ;

Rossi, P. R. F. ;

Troquay, R. P. T. ;

Libby, P. ;

Glynn, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12) :1119-1131

[3] Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein [J].

Ridker, Paul M. ;

Danielson, Eleanor ;

Fonseca, Francisco A. H. ;

Genest, Jacques ;

Gotto, Antonio M., Jr. ;

Kastelein, John J. P. ;

Koenig, Wolfgang ;

Libby, Peter ;

Lorenzatti, Alberto J. ;

MacFadyen, Jean G. ;

Nordestgaard, Borge G. ;

Shepherd, James ;

Willerson, James T. ;

Glynn, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (21) :2195-2207

[4] Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial [J].

Ridker, Paul M. ;

MacFadyen, Jean G. ;

Everett, Brendan M. ;

Libby, Peter ;

Thuren, Tom ;

Glynn, Robert J. .

LANCET, 2018, 391 (10118) :319-328

[5]

Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]

← 1 →